Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Rhizen Pharmaceuticals SA
The Maximum tolerated dose (MTD) will be determined based on the safety, pharmacokinetic (PK) and efficacy data. Safety analyses include AE's, AE's related to the drug, SAE's, laboratory values, vitals/ ECG and dose limiting toxicity (DLT). PK include measurement of peak plasma concentration (Cmax), area under the plasma concentration versus the time curve (AUC), time of maximum concentration observed (Tmax). Efficacy analyses include overall response rate (ORR) and duration of response (DOR).
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Refractory to or relapsed after at least 1 prior treatment line.
ECOG performance status ≤2
Patients must be ≥18 years of age
Able to give a written informed consent.
You may not be if
Any cancer therapy in the last 4 weeks or limited palliative radiation \<2 weeks
Patients with HBV, HCV or HIV infection
Autologous hematologic stem cell transplant within 3 months of study entry. Allogeneic hematologic stem cell transplant within 12 months.
Previous therapy with GS-1101 (CAL-101, idelalisib), IPI-145, TGR-1202 or any drug that specifically inhibits PI3K/ mTOR (including temsirolimus, everolimus), AKT or BTK Inhibitor (including Ibrutinib).
Patients on immunosuppressive therapy including systemic corticosteroids.
Patients who are receiving chronic systemic anticoagulation therapy (warfarin sodium or heparin, etc.).
Patients with known history of liver disorders.
Patients with uncontrolled Diabetes Type I or Type II
Any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study.